Australian Alzheimer's study to use Navidea's imaging agent

07/17/2013 | (free registration)

Navidea Biopharmaceuticals announced that an Australian clinical study will use its NAV4694 beta-amyloid imaging candidate instead of the Pittsburgh Compound B radiotracer. The Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Aging will use NAV4694 for its Alzheimer's disease and mild cognitive impairment research.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA